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Background: Systemic inﬂammation induced by sterile or infectious insults is associated with an enhanced sus-
ceptibility to life-threatening opportunistic, mostly bacterial, infections due to unknown pathogenesis. Natural
killer (NK) cells contribute to the defence against bacterial infections through the release of Interferon (IFN)
γ in response to Interleukin (IL) 12. Considering the relevance of NK cells in the immune defencewe investigated
whether the function of NK cells is disturbed in patients suffering from serious systemic inﬂammation.
Methods: NK cells from severely injured patients were analysed from the ﬁrst day after the initial inﬂammatory
insult until the day of discharge in terms of IL-12 receptor signalling and IFN-γ synthesis.
Findings: During systemic inﬂammation, the expression of the IL-12 receptor β2 chain, phosphorylation of signal
transducer and activation 4, and IFN-γ production on/in NK cells was impaired upon exposure to Staphylococcus
aureus. The profound suppression of NK cells developed within 24 h after the initial insult and persisted for sev-
eral weeks. NK cells displayed signs of exhaustion. Extrinsic changes weremediated by the early and long-lasting
presence of growth/differentiation factor (GDF) 15 in the circulation that signalled through the transforming
growth factor β receptor I and activated Smad1/5. Moreover, the concentration of GDF-15 in the serum inversely
correlated with the IL-12 receptor β2 expression on NK cells and was enhanced in patients who later acquired
septic complications.
Interpretation: GDF-15 is associated with the development of NK cell dysfunction during systemic inﬂammation
and might represent a novel target to prevent nosocomial infections.
Fund: The study was supported by the Department of Orthopaedics and Trauma Surgery, University Hospital
Essen.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Systemic inﬂammation represents a common state of the immune
system of critically ill patients admitted to the intensive care unit
(ICU) and can be associated with life-threatening multiple organ failure
and poor long-term outcome [1–3]. Peripheral infection and tissue
injury (e.g. induced by a mechanical insult or by self-destruction in au-
toimmunity) induce local inﬂammation that aims to restore homeosta-
sis [4]. In contrast, severe infectious or traumatic insults induce
uncontrolled systemic inﬂammation due to the acute and massive re-
lease of pathogen-associated molecular patterns (PAMPs) and
damage-associated molecular patterns (DAMPs), respectively, into the
circulation [5]. Less appreciated so far is the fact that systemic inﬂam-
mation, independent of its origin, is paralleled by the development of
immunosuppression and thereby accounts for 4 million nosocomial in-
fections in ICUs per year in Europe [6]. Consequently, severe tissue
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injury e.g. as a result of both surgical intervention as well as accidental
trauma, not only enhances the susceptibility of patients to nosocomial
infections but also promotes the growth of metastasis in case of cancer
patients [7,8]. Why some patients succumb to septic complications
while others do not despite a similar degree of injury is still a matter
of debate. In addition, no reliable marker exists so far that allows the
identiﬁcation of patients who are prone to infectious complications
and accordingly might be stratiﬁed for speciﬁc therapy.
Anti-inﬂammatory mechanisms usually arise time-delayed to the
onset of inﬂammation as part of the tightly regulated process of resolu-
tion [9]. Thus, the co-existence of systemic inﬂammation and immuno-
suppression in critically ill patients represents a particular pattern of
immune disturbance that warrants further investigation [10].
Cells of the innate immune system such as neutrophils, macro-
phages, dendritic cells, and natural killer (NK) cells play a central role
in the defence against bacterial infections. Macrophages and neutro-
phils are professional phagocytes and efﬁciently take up and eliminate
invading pathogens. However, in the absence of adequate stimulation
by Interferon (IFN) γ they possess only limited bactericidal capacity.
NK cells are a major source of IFN-γ during bacterial infections [11].
Two major subsets of human NK cells are distinguished in peripheral
blood: CD56dim NK cells primarily act as cytotoxic effector cells that
eradicate tumour cells and virus-infected cells whereas CD56bright NK
cells showweak cytotoxic activity but release substantial amounts of di-
verse cytokines [12,13]. CD56bright NK cells represent approximately
10% of the human circulating NK cell population and secrete high
amounts of IFN-γ in response to interleukin (IL) 12. The corresponding
IL-12 receptor (IL-12R) is a heterodimer and consists of a constitutively
expressed β1 chain and a β2 chain that is expressed only upon stimula-
tion of the cell [14]. Ligation of the IL-12R induces the phosphorylation
of Signal Transducer and Activator of Transcription (STAT) 4 that en-
ables the transcription of the IFNG gene [15,16].
Dendritic cells and to a lesser extent monocytes/macrophages serve
as accessory cells for NK cell activation as they secrete IL-12 upon con-
tact with PAMPs [17,18]. NK cell-derived IFN-γ further increases the
release of IL-12, thus creating a positive feedback loop between acces-
sory cells and NK cells that may be restricted by anti-inﬂammatory cy-
tokines in the local microenvironment [19,20]. Additionally, the extent
of IFN-γ synthesis is regulated by the balance of stimulatory (e.g.
NKG2D) and inhibitory receptors (e.g. NKG2A) on the surface of NK
cells and the presence of the respective ligands on accessory cells
[21,22].
NK cells from patients who suffer from infectious or non-infectious
systemic inﬂammation display a defective IFN-γ production of un-
known origin [23,24]. Here, we investigated the mechanisms underly-
ing the disturbed function of NK cells in patients suffering from severe
systemic inﬂammation. We discovered a profound and long-lasting
suppression of CD56bright NK cells in terms of IFN-γ synthesis that was
associated with an impaired IL-12R signalling due to cell-intrinsic and
-extrinsic changes.Moreover,we identiﬁed circulating growth/differen-
tiation factor (GDF) 15 as a novel potential target for the restoration of
NK cell function and as marker for patients at high risk for nosocomial
infections.
2. Materials and methods
2.1. Patients and study design
Inclusion criteria for this study were an Injury Severity Score (ISS)
≥16 and age ≥ 18 years. Patients with isolated head injury, HIV infection,
and immunosuppressive therapies were excluded. Patients were en-
rolled at four different level I trauma centres (University Hospital
Essen, Germany; University Hospital Dusseldorf, Germany; UlmUniver-
sity Medical Centre, Germany; and University Hospital Zurich,
Switzerland). Group 1: Heparinized blood and serum were obtained
from patients (n= 10) who were admitted to the emergency room at
the University Hospitals of Essen and Dusseldorf between January and
September 2013. Blood was drawn 24 h (40 ml), 4 d (10 ml), 6 d
(10 ml), and 8 d (40 ml) after injury as well as on the day of discharge
or of the transfer to another hospital or rehabilitation centre (40 ml).
The majority of these patients sustained severe to critical injuries of
the head/neck, thorax, and extremities due to accidental trauma or to
fall. None of the patients suffered from severe basal diseases that re-
quired strong medication. At each time point the planned blood with-
drawal was approved by the responsible physician. Some blood
samples were insufﬁcient to perform all analyses and caused missing
values that are indicated in the ﬁgure legends. As control, whole blood
from healthy volunteers (n= 8) who were recruited from the labora-
tory staff and from outside was analysed.
For subsequent analyses of circulating factors, sera from patients
who fulﬁlled the inclusion criteria and whowere comparable to the pa-
tients in group 1 in terms of age, sex, and morbidity were selected from
a collection of samples located at two different sites (the personwho se-
lected the sera was blinded to the data obtained from group 1):
Research in context
Evidence before the study
Critically ill patients who suffer from systemic inﬂammation
(e.g. caused by major traumatic/surgical injuries or severe infec-
tions) are highly susceptible to life-threatening nosocomial infec-
tions during their stay on the intensive care unit. The
pathogenesis of the impaired immune defence during systemic
inﬂammation is still poorly understood. Accordingly, efﬁcient
therapeutic interventions that reduce the risk for opportunistic
infections are lacking. Moreover, there exists no reliable marker
that identiﬁes patients who are at advanced risk for infectious
complications.
Added value of this study
Natural killer cells secrete IFN-γ upon stimulation with IL-12 and
thereby contribute to the efficient elimination of invading bacteria.
In this study, we discovered a profound suppression of the IL-12/
IFN-γ axis in circulating human natural killer cells that developed
early after a severe inflammatory insult and was maintained for
several weeks. The suppression of natural killer cells was largely
mediated by a soluble factor in the serum that signalled through
the TGF-β receptor I. We provide evidence that this soluble factor
was GDF-15 that was released into the blood at high concentra-
tion throughout the observation period of the patients and in-
versely correlated with IL-12 receptor expression on natural killer
cells. Importantly, patients who later developed nosocomial infec-
tion displayed enhanced levels of GDF-15 as soon as 1 d after the
initial inflammatory insult.
Implications of all the available evidence
Natural killer cells rapidly lose their capacity to secrete IFN-γ during
systemic inflammation and consequently might fail to support im-
mune defencemechanisms against invading pathogens. Inhibitors
of the TGF-β receptor I that are already tested in clinical studies for
cancer therapy restore NK cell function and might be appropriate
to reduce infectious complications in systemic inflammation.
Moreover, GDF-15 that signals through the TGF-β receptor I
might serve as an early marker to identify patients at high risk for
nosocomial infections.
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Group 2: Serum samples (1 and 5 d after injury) from patients (n=
19)whowere admitted to the emergency room at theUniversityHospi-
tal Ulm between December 2013 and July 2016.
Group 3: Serum samples (1 and 5 d after injury) from patients (n=
20)whowere admitted to the emergency roomat theDivision of Trauma
Surgery at the University Hospital Zurich from December 2009 to March
2012. Sera from patients who developed a septic complication (n=10)
and patients who remained free of sepsis (n=10) were selected. Based
on the Systemic Inﬂammation score (SI score), secondary sepsis in in-
jured patients was deﬁned as ΔSI score (difference of SI score between
two consecutive timepoints) ≥+2points in concomitancewith an infec-
tious focus or positive blood cultures [25,26]. The characteristics of pa-
tients of all groups and control subjects are listed in Table 1.
The studywas approved by the local ethic committees of theUniver-
sity Hospital Essen, the University Hospital Dusseldorf, the University
Ulm, and the University Hospital Zurich. After veriﬁcation of the inclu-
sion criteria by an independent physician, thewritten informed consent
was obtained from the patients or their legal representatives. The study
was conducted according to the Declaration of Helsinki.
2.2. Preparation of mononuclear cells and serum
Heparinized blood was used to isolate peripheral blood mononu-
clear cells (PBMC) using a standard protocol for Ficoll density gradient
centrifugation and subsequent red blood cell lysis. The PBMC were im-
mediately used for FACS analyses and cell culture.
Sterile serumwas obtained from clottedwhole blood of patients and
healthy control subjects after centrifugation at 2000g for 10 min. The
sera were aliquoted and stored at −20 °C until use. For depletion of
GDF-15, 96-well ﬂat-bottom plates (MaxiSorp, NUNC, Thermo Fisher
Scientiﬁc, Waltham, MA) were coated with antibodies against human
GDF-15 (2 μg/ml; clone I47627, Biotechne, Abingdon, UK) or with the
corresponding mouse IgG2b isotype control antibodies (2 μg/ml; clone
20116, Biotechne) for 18 h. The plates were each washed twice with
PBS/0·05% Tween 20 and with PBS. After blocking with 1% BSA for 1 h
and washing, serum (20% in PBS v/v) was added to the coated wells
for 1 h at 4 °C. Thereafter, the serum was aspirated and transferred
into fresh plates coated with identical antibodies. The transfer of the
sera into freshly coated wells was performed in total 3 times. After
each step, the remaining concentration of GDF-15 in the sera was quan-
tiﬁed by ELISA. The efﬁciency of the depletion of GDF-15 was 100% and
70% for sera from healthy controls and the patients' sera, respectively.
2.3. Cell culture
PBMC were cultured in VLE RPMI 1640 Medium (containing stable
glutamine) supplemented with 100 U/ml Penicillin and 100 μg/ml
Streptomycin (Sigma-Aldrich). Depending on the experimental set up,
the culture medium contained 2% or 10% human serum or 10% fetal
calf serum (FCS). Cultures of PBMC were set up at least in triplicates
(4 × 105 cells/well) in 96-well ﬂat bottom plates (BD Biosciences, Hei-
delberg, Germany) at a total volume of 200 μl/well and incubated at
37 °C and 5% CO2 in a humidiﬁed atmosphere.
PBMC were rested for 30 min before addition of 1 ng/ml recombi-
nant human IL-12, 1 ng/ml recombinant human IL-2, 5 ng/ml IL-15,
5 ng/ml IL-18, 10 ng/ml GDF-15 (all cytokines from Biotechne), 4 μM
SB431542 (inhibitor of ALK4, ALK5, and ALK7; Tocris, Biotechne), or 1
μMGW788388 (selective inhibitor of ALK5; Tocris)where indicated. Di-
methyl sulfoxide (DMSO) was used as the solvent of the inhibitor and
served as negative control. Thirty min later, PBMC were stimulated
with heat-inactivated S. aureus (Pansorbin Cells Standardized, 0.05%
(v/v), Calbiochem, Merck, Darmstadt, Germany or heat-killed S. aureus
(HKSA), 0.5 × 106 bacteria /ml, Invivogen, San Diego, CA), inactivated
L.monocytogenes (15 × 106/ml; Invivogen, San Diego, CA), or ssRNA40
(250 ng/ml; Invivogen) as indicated. Unstimulated PBMC served as neg-
ative control. After 18 h, PBMC were subjected to ﬂow cytometry and
the supernatants were harvested and stored at−20 °C.
Monocytes were isolated from PBMC of healthy donors using CD14
MicroBeads (Miltenyi) as recommended by the manufacturer. Mono-
cyteswere seeded in 96-well plates (1.5 × 105/well) inmedium supple-
mented with 1 % serum from healthy control subjects or from patients.
Monocytes were stimulated with S. aureus in the absence or presence of
10 ng/ml human recombinant IFN-γ (Biotechne). The supernatant was
harvested after 18 h and stored at−20 °C.
2.4. Flow cytometry
Cell surface marker staining was performed as described previously
[27]. The following ﬂuorochrome-labelled antibodies were used: anti-
CD3 (clone MEM-57, ﬂuorescein-labelled, ImmunoTools, Friesoythe,
Germany), anti-CD56 (clone CMSSB, allophycocyanin-labelled,
eBioscience, Thermo Fisher Scientiﬁc), anti-IL-12Rβ2 chain (clone 2B6/
12β2, phycoerythrin (PE) -labelled, BD Biosciences), anti-CD16 (clone,
3G8, PE-Cy7-labelled, Biolegend, San Diego, CA), anti-NKG2D (clone
1D11, PE-labelled, BioLegend), anti-CD62L (clone DREG-56, PE-
labelled, BioLegend), anti-IL-12Rβ1 chain (clone 2.4E6, PE-labelled, BD
Biosciences), anti-CD69 (clone FN50, PE-labelled, ImmunoTools), anti-
CD25 (clone MEM-181, PE-labelled, ImmunoTools), anti-CD107a
(clone H4A3, PE/Cy5-labelled BD Biosciences).
Intracellular staining for phosphorylated STAT4 and Smad1/8 pro-
teinswas performed after 18 h of culture using antibodies against phos-
phorylated STAT4 (pY693; clone 38/p-Stat4, PE-labelled, BD
Biosciences), phosphorylated Smad1/8 (cross-reactive with pSmad5;
clone N6-1233, PE-labelled, BD Biosciences), and the Foxp3/Transcrip-
tion Factor StainingBuffer Set (eBioscience) asdescribedpreviously [27].
For intracellular staining of IFN-γ, GolgiStop (BD Biosciences) was
added to the cells for additional 5 h. After surface staining of CD3 and
CD56 the cells were ﬁxed and permeabilized using BD Cytoﬁx/
Cytoperm (BD Biosciences). Intracellular staining with PE-labelled anti-
bodies against IFN-γ (clone 4S·B3, BioLegend) was performed in Per-
meabilization Buffer (BD Biosciences) for 20 min at 4 °C followed by
washing with Cell Wash (BD Biosciences).
In general, staining with the corresponding isotype control antibod-
ies was performed to determine the threshold for speciﬁc staining. The
threshold was set at 1% false positive cells. All Data were acquired using
a FACSCalibur (BD Biosciences) and were analysed using CellQuest Pro
software (BD Biosciences).
For degranulation assays, PBMC cultures were set up in medium
containing 4% FCS. Monoclonal antibodies against CD107a were added
and cells were incubated with K562 target cells for 3 h. Control samples
were incubated without target cells to detect spontaneous degranula-
tion. Thereafter, samples were stained with anti-CD3 and anti-CD56
antibodies.
Table 1
Patient characteristics.
Group 1 Group 2 Group 3
Controls
n = 8
Injury
n = 10
Injury
n = 19
Injury
n = 20
Age [y] 43 (38–47) 48 (42–58) 47 (28–56) 49 (27–63)
Sex m/f (% m) 6/2 (75) 8/2 (80) 15/4 (82) 15/5 (75)
Injury severity score (ISS) 25 (22−30)⁎ 34 (29–41) 36 (33–45)
SOFAmax 11(10–15) 11(8–13) 9 (4–14)
ICU length of stay 27 (14–33) 15 (6–22) 15 (3−31)
Sepsis (%) 0 0 50
Sepsis diagnosis [d] 9 (7–15)
Characteristics of control subjects and recruited patients (groups 1 to 3). Values are given
as median (interquartile range). Differences between the three groups of patients were
tested using the Kruskal-Wallis Test followed by Dunn's Multiple Comparison test. Differ-
ences between controls and patients within group 1were tested using theMannWhitney
Test. Discrete variables were tested using the χ2 test.
⁎ , p b 0·05 vs. group 3; SOFAmax, maximal Sequential Organ Failure Assessment score
within the ﬁrst 5 d.
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2.5. Quantiﬁcation of cytokines and C-reactive protein
Supernatants were assessed for the concentration of human IL-12
using a highly sensitive ELISA (Quantikine, R&D Systems, Biotechne) ac-
cording to manufacturer's instructions. Human GDF-15, IL-6, and TGF-
β1 in the sera were quantiﬁed by ELISA (DuoSet, R&D Systems,
Biotechne). For examination of active TGF-β1 the sera were not acidi-
ﬁed. The detection limit was 0.8 pg/ml for GDF-15, 7.8 pg/ml for IL-12,
9.4 pg/ml for IL-6, and 31.3 pg/ml for TGF-β1. C-reactive protein (CRP)
levels were obtained from routine clinical diagnostics.
2.6. Reporter assay for Smad activation
PBMC were infected with adenoviruses containing the Smad1/5 re-
porter construct Ad5-BRE-Luc (‘BRE’) or the Smad2/3 reporter construct
Ad5-CAGA9-MLP-Luc (‘CAGA’; both kindly provided by Dr. O.
Korchinsky and Prof. P. ten Dijke) as previously described [28–30]. The
reporter constructs enabled Smad-driven luciferase activity. The mix-
ture of cells and viruseswere cultured in RPMI 1640medium containing
2mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 2% FCS
in a 96-well plate for 24 h. Thereafter, sera or recombinant human GDF-
15 (100 ng/ml; Lot STO0917032 and STO2616061, Biotechne), each in
the absence or presence of 5 μM SB431542, was added. Where indi-
cated, the sera were depleted of GDF-15 as described above prior to
use in the reporter assay. Recombinant bone morphogenetic protein
(BMP) 2 (10 ng/ml; Peprotech, Hamburg, Germany) or transforming
growth factor (TGF)β1 (5ng/ml; Peprotech) served as positive controls.
All samples were set up in quadruplicates. After 48 h, luciferase signals
were detected with the help of the Steady-Glo Luciferase Assay System
(Promega, Madison, USA) as recommended by themanufacturer. Lucif-
erase signals were measured immediately (Omega plate reader, BMG
labtech). The infection efﬁciency was determined by ﬂuorescence mi-
croscopy using viral particles containing an Ad5-GFP construct and
ranged between 10 and 15% of PBMC. All values were normalized to
PBMC that were cultured in medium only.
2.7. Statistical analyses
Preparation of graphs and statistical analyses were performed using
GraphPad Prism Version 5 (GraphPad Software, La Jolla, USA). Depend-
ing on the nature of the data parametric or non-parametric, paired or
unpaired tests (two-sided Student's t-test, ANOVA, Mann Whitney U
test, Wilcoxon signed rank test, Kruskal-Wallis test, or Friedman test)
were used for statistical analyses as indicated in the ﬁgure legends. Cor-
relations between two parameters were calculated using Spearman r
analysis.
3. Results
3.1. Systemic inﬂammation impairs S. aureus-induced IFN-γ production by
CD56bright NK cells
We selected patientswho suffered life-threatening severe injury as a
model for systemic inﬂammationwith deﬁned onset of the insult. As ex-
pected, increased levels of CRP and IL-6 were detected in the sera of the
patients indicating ongoing inﬂammation (Suppl. Fig. 1). We analysed
the capacity of CD56bright NK cells to produce IFN-γ upon exposure of
PBMC to inactivated S. aureus bacteria. CD56bright NK cells from patients
were signiﬁcantly impaired in IFN-γ production as soon as 1 day after
injury and remained suppressed throughout the whole observation pe-
riod (Fig. 1a, b) which terminated at the day of discharge or of transfer
to another hospital approximately 4 weeks later (Table 1). In contrast,
the percentage of CD56bright NK cells did not differ throughout the ob-
servation period (Suppl. Fig. 2).
The expression of the stimulatory receptor NKG2D on CD56bright NK
cells was transiently reduced on day 1 after injury and recovered
thereafter (Suppl. Fig. 3a). In contrast, the expression of CD62L that is
decreased upon NK cell activation did not differ at any time point
(Suppl. Fig. 3b) [31]. Likewise, the expression of CD69 and CD25 did
not change signiﬁcantly after injury (Suppl. Fig. 3c, d).
The suppression of CD56bright NK cell function in systemic inﬂamma-
tion might be mediated by cell-intrinsic changes in PBMC and/or by
changes in the microenvironment. When the autologous serum in the
cell culture medium was replaced by FCS to generate a microenviron-
ment free of human factors only the IFN-γ production on day 8 after in-
jury signiﬁcantly differed from control subjects (Fig. 1c). In contrast, the
target cell-induced degranulation of CD56bright and CD56dim NK cells
after injury (indicated by the expression of CD107a)wasnot diminished
(Suppl. Fig. 4). Thus, systemic inﬂammation impairs the IFN-γ synthesis
of CD56bright NK cells after stimulation of PBMC with S. aureus in both,
intrinsic and extrinsic, manner.
3.2. IL-12 does not restore the IFN-γ production by CD56bright NK cells
IL-12 is indispensable for the S. aureus-induced IFN-γ production by
CD56bright NK cells and might play an essential role in the suppressed
IFN-γ response in systemic inﬂammation [27]. Indeed, the patients'
PBMC secreted less IL-12 after exposure to S. aureus in autologous
serum (Fig. 2a). The addition of recombinant IL-12 increased the fre-
quency of IFN-γ-producing CD56bright NK cells from healthy controls
as well as from patients though the latter remained inferior in IFN-γ
synthesis especially on day 8 (Fig. 2b). The recombinant IL-12-induced
increase in the percentage of IFN-γ+ CD56bright NK cells was signiﬁ-
cantly lower on day 8 than on day 1 after injury (Fig. 2c). The IFN-γ
Fig. 1. Suppressed capacity of CD56bright NK cells to secrete IFN-γ in response to S. aureus in
systemic inﬂammation. PBMC from severely injured patients and from healthy control
subjects (group 1; n = 10) were stimulated with heat-inactivated S. aureus in the
presence of 10% autologous serum (a, b) or FCS (c). (A) Gating strategy of
CD3−CD56bright NK cells and representative dot plots for a control subject and a patient
1 d after injury in the absence (none) or presence of S. aureus. Numbers indicate the
percentage of IFN-γ+ cells among gated CD56bright NK cells. (b, c) Cumulative data of
the percentage of IFN-γ+ CD56bright NK cells from individual control subjects and
patients in the presence of autologous serum (b) or FCS (c). For reasons of clarity the
values obtained in the absence of S. aureus are not shown as they did not exceed 3%.
Horizontal lines indicate the median and interquartile range. Statistical analyses were
performed using the Friedman test (* p b 0.05; ** p b 0.01) for comparison within the
group of patients and the Mann Whitney U test (## p b 0.01; ### p b 0.001) for
comparison of patients with healthy controls. C, controls; D, day of discharge; iso,
isotype control.
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synthesis in CD56dim NK cells was similarly impaired after injury and
was not restored by exogenous IL-12 though it was much weaker than
in CD56bright NK cells (Suppl. Fig. 5a, b).
Similarly, on day 8 after injury CD56bright NK cells only weakly
responded to IL-2 (Fig. 2d) that otherwise led to an increased IFN-γ syn-
thesis in line with previous reports [32]. Importantly, the patients' NK
cells strongly responded to a potent cytokine cocktail consisting of IL-
12, IL-18, and IL-15 (Suppl. Fig. 6). Thus, suppression of CD56bright NK
cells in systemic inﬂammation is associated with a low responsiveness
of the cells to IL-12 and IL-2.
3.3. The impaired IFN-γ synthesis correlates with reduced IL-12Rβ2 expres-
sion and STAT4 phosphorylation
To evaluate themechanisms underlying the reduced responsiveness
of NK cells to IL-12 after injury, we determined their expression
of the IL-12 receptor. CD56bright NK cells constitutively expressed the
IL-12Rβ1 chain at comparable levels as did cells from healthy control
subjects (Suppl. Fig. 3e) whereas the β2 chain was only expressed
after exposure to S. aureus (Fig. 3a). In contrast to cells from controls,
the patients' NK cells weakly expressed the IL-12Rβ2 chain throughout
the whole observation period (Fig. 3b). In the absence of human serum,
the suppressed IL-12Rβ2 expression was observed only on day
8 (Fig. 3c). CD56brightCD16+ NK cells display a more mature phenotype
and expressed less IL-12Rβ2 (Suppl. Fig. 7a) than CD56brightCD16−
NK cells [33]. The percentage of CD16+ cells among CD56bright NK
cells did not differ between healthy control subjects and patients
(Suppl. Fig. 7b) indicating that the reduced IL-12Rβ2 expression on
CD56bright NK cells was not caused by an altered ratio of CD16+ and
CD16− cells.
Engagement of the IL-12Rβ2 chain results in phosphorylation of the
transcription factor STAT4 that is essential for IFNG gene transcription in
the nucleus [15,16]. Exposure of PBMC to S. aureus clearly increased the
level of STAT4 phosphorylation in CD56bright NK cells from healthy con-
trols but merely in NK cells 1 d and 8 d after injury (Fig. 3d, e). The ex-
pression of the IL-12Rβ2 chain on the cell surface signiﬁcantly
correlated with STAT4 phosphorylation (Fig. 3f). Likewise, CD56dim NK
cells displayed reduced IL-12Rβ2 expression and STAT4 phosphoryla-
tion after severe injury (Suppl. Fig. 5c, d). Thus, the impaired capacity
of CD56bright NK cells to produce IFN-γ in systemic inﬂammation
is associated with suppressed IL-12Rβ2 expression and STAT4
phosphorylation.
3.4. The suppression of CD56bright NK cells is mediated by a circulating
factor
The expression of IL-12Rβ2 and the production of IFN-γ by the pa-
tients' NK cells were at least partly restored when the stimulation of
the cells occurred in the absence of the autologous serum except on
day 8. Consequently, we hypothesized that serum acquired a suppres-
sive capacity on NK cells after severe injury. To address this issue, cul-
tures of PBMC from healthy volunteers were set up with pooled
serum from the group of healthy control subjects (that served as refer-
ence value and was set as 100%) or with serum of individual patients
from day 1 and day 8 after injury (termed ‘d1-serum’ and ‘d8-serum’,
respectively, hereafter) andwere stimulated with S. aureus. In the pres-
ence of d8-serum CD56bright NK cells appeared to produce less IFN-γ
than in the presence of the corresponding d1-serum though this effect
did not reach statistical signiﬁcance (Fig. 4a, b). The IFN-γ production
of CD56bright NK cells from healthy donors in the presence of the
serum of a given patient correlated with the IFN-γ production of the
CD56bright NK cells of the same patient (Fig. 4c). Moreover, the patients'
sera did not only suppress the IFN-γ production in response to S. aureus
but also in response to other pathogen or pathogen-derived compo-
nents, i.e. Listeria monocytogenes and viral single-stranded RNA (Suppl.
Fig. 8).
Further examination of the effect of the patients' sera on CD56bright
NK cells from healthy donors revealed a signiﬁcant decrease in the
S. aureus-induced expression of IL-12Rβ2 by d8-serum in comparison
to d1-serum or to the pooled serum from healthy control subjects
(Fig. 5a, b). Moreover, the expression of IL-12Rβ2 clearly correlated
with the production of IFN-γ (Fig. 5c). Remarkably, the d1-sera and
evenmore the d8-sera interfered with the S. aureus-induced phosphor-
ylation of STAT4 (Fig. 5d). There was no correlation between STAT4
phosphorylation and IFN-γ production (data not shown).
Next, we asked whether the patients' sera impaired monocytes
for IL-12 synthesis that in turn led to a decreased IFN-γ response by
CD56bright NK cells. In line with a previous study [20] no IL-12 was re-
leased by isolated monocytes from healthy donors after exposure to
S. aureus alone. Remarkably, when the monocytes were boosted by the
addition of recombinant IFN-γ they secretedmuchmore IL-12when cul-
tured in the presence of the patients' sera (Fig. 5e). Thus, a circulating fac-
tor inhibits the IL-12/IFN-γ axis in CD56bright NK cells after severe injury.
3.5. Signalling through TGF-β receptor I contributes to NK cell suppression
IL-10 and TGF-β are regulatory cytokines that are known to limit the
IFN-γ production byNK cells andmight contribute to the suppression of
CD56bright NK cells in systemic inﬂammation [34,35]. Blocking of IL-10
during stimulation of PBMC with S. aureus slightly increased the IFN-γ
production of CD56bright NK cells from controls but it was ineffective
in case of the patients' NK cells (data not shown).
We investigated the potential role of members of the TGF-β family
using SB431542, a small molecule inhibitor of the TGF-βRI (also
known as activin-like kinase (ALK) 5). To enable parallel analysis, the
sera from all patients were pooled for each time point after injury. The
Fig. 2. Decreased responsiveness of CD56bright NK cells to IL-12 in systemic inﬂammation.
PBMC from patients and fromhealthy control subjects (group 1; n=10) were stimulated
with inactivated S. aureus in the presence of 10% autologous serum. (a) Content of IL-12 in
the supernatant. (b, c, d) PBMC were stimulated with inactivated S. aureus together with
recombinant human IL-12 (n = 9) or IL-2. Percentage of IFN-γ+ CD56bright NK cells
upon supplementation with IL-12 (b). IL-12-induced (c) or IL-2-induced (d) increase in
the percentage of IFN-γ+ CD56bright NK cells expressed as the difference in the
percentage of IFN-γ+ cells (Δ) obtained in the presence and absence of the respective
cytokine. Data are shown as Tukey box plots. Horizontal lines indicate the median and
interquartile range. Statistical analyses were performed using the Friedman test (* p b
0.05; ** p b 0.01) for comparison within the group of patients and the Mann Whitney U
test (## p b 0.01; ### p b 0.001) for comparison of patients with healthy controls. C,
controls; D, day of discharge.
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expression of IL-12Rβ2 and the production of IFN-γ by CD56bright NK
cells were suppressed by each pool of the patients' sera in a TGF-βRI-
dependent manner (Fig. 6a). The minor effect of SB431542 on NK cells
in the presence of serum from healthy control subjects might be ex-
plained by the inhibition of the autoregulatory activity of NK cell-
derived TGF-β [36]. Analyses of the patients' individual sera of day 6
after injury conﬁrmed the increased IL-12Rβ2 expression upon inhibi-
tion of the TGF-βRI (Fig. 6b). Alternative inhibition of ALK5 by
GW788388 likewise restored the IFN-γ synthesis of CD56bright NK cells
in the presence of the patients' sera (Suppl. Fig. 9). Importantly, the pa-
tients' sera did not generally suppress the function of NK cells as the ac-
tivity for degranulation remained unchanged (Suppl. Fig. 10).
The concentration of TGF-β1 as the major ligand of the TGF-βRI in
the patients' sera did not remarkably exceed the levels found in the
sera from control subjects at any time point after injury (Suppl.
Fig. 11). GDF-15, also known as macrophage inhibitory cytokine-1, is
a distant member of the TGF-β family and may signal through the
TGF-βRI [37–39]. The concentration of GDF-15 in the serum of healthy
control subjects was within the normal range (b1200pg/ml). We
found extremely high levels of GDF-15 in the patients' sera as soon as
1 d after injury that exceeded the levels in sera from healthy control
subjects by almost 20-fold and remained high at least until day 8
(Fig. 6c). Correlation analyses indicated an inverse relationship between
the content of GDF-15 in the serum and the expression of the IL-12Rβ2
(Fig. 6d) and IFN-γ (Suppl. Fig. 12) of CD56bright NK cells from healthy
donors upon exposure to this serum and stimulation with S. aureus.
To get insight into the signalling of GDF-15 in PBMCupon their expo-
sure to the sera, the canonical pathway of the TGF-βRI involving the ac-
tivation of Smad2/3 and/or Smad 1/5/8 was investigated using
transfection with speciﬁc reporter constructs. According to Fig. 6a the
reversal of CD56bright NK cell suppression by inhibition of the TGF-βRI
was most prominent for sera obtained on day 4 and 6 after injury.
Therefore, d5-serum was selected and applied to the reporter assays.
The sera from healthy control subjects and from patients induced the
activation of Smad 1/5 that was almost completely blocked in the pres-
ence of the TGF-βRI inhibitor (Fig. 7a). In contrast, the sera did not cause
the activation of Smad2/3 (Fig. 7a). Prior depletion of GDF-15 from the
serum clearly reduced the activation of Smad1/5 (Fig. 7b). Accordingly,
recombinant GDF-15 triggered the Smad1/5 reporter construct in a
TGF-βRI-dependent manner but not the Smad2/3 reporter construct
(Fig. 7b). Moreover, intracellular ﬂow cytometry revealed an increased
expression of phosphorylated Smad1/8 in CD56bright NK cells after expo-
sure to the patients' sera (Suppl. Fig. 13).
The sera that had beendepleted of GDF-15were additionally applied
to PBMC to address the IL-12Rβ2 expression. However, we could
not draw any conclusions from these experiments since NK cells failed
to express the IL-12Rβ2 chain upon stimulation with S. aureus when
the serum had been exposed to the isotype control antibodies (data
not shown). Thus, GDF-15 circulates at high levels during systemic in-
ﬂammation, activates Smad1/5 downstream of the TGF-βRI, and is
linked with the suppressive activity of the patients' sera on CD56bright
NK cells.
Fig. 3. Reduced expression of IL-12Rβ2 and phosphorylation of STAT4 on/in CD56bright NK cells in systemic inﬂammation. PBMC from patients and from healthy control subjects (group 1;
n= 10) were stimulated with inactivated S. aureus in the presence of autologous serum (a, b, d–f) or FCS (c). (a) Representative dot plots for staining of IL-12Rβ2 on CD56bright NK cells
from a control subject and a patient 1 d after injury. Numbers indicate the percentage of positive cells. (b) Cumulative data of the percentage of IL-12Rβ2+ CD56bright NK cells in the
presence of autologous serum. Note, due to insufﬁcient cell numbers only n= 8–9 values were available for d1 and d8. (c) Percentage of IL-12Rβ2+ CD56bright NK cells in the presence
of FCS (n = 8 on d8). (d) Representative histograms showing the phosphorylated STAT4 (pSTAT4) expression of unstimulated (none) and stimulated cells from one control subject
and one patient on day 1 after injury. ΔMFI depicts the difference between the mean ﬂuorescence intensity (MFI) of stimulated and unstimulated cells. (e) Cumulative data of the
ΔMFI of CD56bright NK cells from controls and patients 1 or 8 d after injury (each n = 8) or at the day of discharge presented as Tukey box plots. Horizontal lines indicate the median
and interquartile range. (f) Spearman correlation between the percentage of IL-12Rβ2+ cells (obtained from Fig. 3b) and ΔMFI pSTAT4 (obtained from Fig. 3e). Statistical analyses
were performed using the MannWhitney U test. #, p b 0.05; ##, p b 0.01; ###, p b 0.001 versus controls. c, control subjects; D, day of discharge; iso, isotype control.
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3.6. Early elevated levels of GDF-15 are associated with critical illness
In order to gather information on the clinical relevance of the high
levels of circulating GDF-15 in systemic inﬂammation, we analysed
sera of an additional group of patients on day 1 and 5 after injury.
These patients were free of signs of sepsis until day 5 but 50% of them
developed a septic complication later on (themedian time point of sep-
sis diagnosis was 9 d after injury; see Table 1). Remarkably, as soon as
1 d after injury, patients who later developed sepsis (beyond day
5) displayed signiﬁcantly higher levels of GDF-15 than those who
remained free of septic complications (Fig. 8). Moreover, the GDF-15
levels on day 1 signiﬁcantly correlated with the degree of morbidity es-
timated by the maximal Sequential Organ Failure Assessment (SOFA)
score during the ﬁrst 5 days (Table 2). No signiﬁcant correlation of the
GDF-15 concentrationwith the age orwith the injury severity of the pa-
tientswas detected (Table 2). Thus, GDF-15 is associatedwith enhanced
morbidity and risk for septic complication in systemic inﬂammation.
4. Discussion
The present study shows for the ﬁrst time that in parallel to ongoing
systemic inﬂammation circulating CD56bright NK cells display a state of
deactivation in terms of IFN-γ synthesis that persists for several
weeks. Deactivation or exhaustion of NK cells is a well-known phenom-
enon in cancer. In that case CD56dimNKcells are unable to recognize and
kill tumour cells due to insufﬁcient cytotoxicity, cytokine production,
and increased expression of inhibitory receptors such as PD-1 [40]. In
contrast, degranulation of NK cells was not reduced after severe injury
suggesting that diverse pathomechanisms drive the modulation of NK
cells during systemic inﬂammation and in cancer.
In line with a previous study PBMC from severely injured patients
released reduced levels of IL-12 after exposure to S. aureus, a ﬁnding
that has been ascribed to the deactivation of monocytes [41,42]. More-
over, we identiﬁed a disturbed expression of the β2 chain of the IL-
12R and downstream STAT4 phosphorylation on/in CD56bright NK cells
that was associated with impaired IFN-γ synthesis. A selective disorder
of the IL-12 signalling pathway might explain why injury did not inter-
fere with degranulation that is triggered by synergistic engagement of
activating receptors such as NKG2D in a cytokine-independent manner.
Since IFN-γ is required to enable robust IL-12 synthesis by monocytes
we assume that both the inappropriate IL-12 secretion by monocytes
and the impaired expression of the IL-12Rβ2 chain on NK cells generate
a negative feedback loop that further aggravates the dysfunction of ac-
cessory cells and CD56bright NK cells during systemic inﬂammation. Con-
sequently, NK cells that are recruited from the circulation into the
infected tissue or into draining lymphoid organs in case of an infectious
insult might be unable to support the elimination of the pathogens due
to their insufﬁcient IFN-γ production. This assumption is supported by
our previous work on a clinically relevant murine model of sterile skel-
etalmuscle injury showing thatNK cells are recruited to the lymphnode
draining the site of injury and interfere with the development of
T helper cell type 1 responses [43]. Though, it remains to be elucidated
whether the NK cells in this mouse model likewise display an insufﬁ-
cient formation of IFN-γ and/or even acquire regulatory activity through
the release of IL-10 [44–46].
Due to the limited sample volume that could be obtained from the
patients we focused on the production of IFN-γ as a relevant mediator
in the defence against bacterial infections. Therefore, we cannot rule
out that after severe injury other mediators such as IL-10 are expressed
at enhanced levels while the production of IFN-γ is suppressed, a state
that may be termed ‘reprogramming’ rather than ‘deactivation’.
Seshadri et al. recently reported an initially decreased but later in-
creased synthesis of TNF-β in NK cells of injured patients in response
to Streptococcus pneumoniae as compared with cells from healthy do-
nors [47]. These temporal changes in cytokine synthesis might reﬂect
signs of reprogramming of NK cells after severe injury. In contrast to
our ﬁndings, the authors did not observe a profound suppression of
IFN-γ synthesis. It is possible that due to the lack of discrimination be-
tween NK cell subtypes in that study the function of the relatively
small population of CD56bright NK cells was blurred by the weak IFN-γ
production of CD56dim NK cells.
The risk of patients for infectious complications is known to peak
around day 8 after injury while CD56bright NK cells were similarly sup-
pressed in IFN-γ synthesis throughout the whole observation period
[48]. Thus, at the ﬁrst glance the early suppression of NK cell-derived
IFN-γ synthesis did not seem to correlate with the delayed onset of in-
fection. We dissected cell-intrinsic and -extrinsic mechanisms that in-
duced qualitative differences in the suppression of CD56bright NK cells.
The intrinsic effect became apparent when the cells were analysed in
the absence of autologous serum. In this human serum-free microenvi-
ronment only CD56bright NK cells from patients 8 d after injurywere sig-
niﬁcantly impaired in IFN-γ synthesis and IL-12Rβ2 expression
suggesting that the cells had acquired a state of exhaustion. But unlike
NK cells in tumours, the function of CD56bright NK cells at that time
point could not be restored by the stimulatory cytokines IL-2 or IL-12
[40]. A global inhibition of the IFN-γ synthesis in the patients' NK cells
could be excluded as they strongly responded to a potent cytokine
cocktail.
Our previous ﬁndings that puriﬁed NK cells from severely injured
patients do not release IFN-γ after stimulation with IL-12/IL-18 support
our hypothesis of intrinsic changes in NK cells 8 d after injury [24]. As
Fig. 4. Serum from injured patients interferes with the IFN-γ synthesis of CD56bright NK
cells from healthy donors. PBMC from healthy donors were stimulated with inactivated
S. aureus in the presence of 10% pooled sera from healthy control subjects or with serum
from individual patients obtained on day 1 and day 8 after injury (group 1; n = 10).
(a) Representative dot plots of intracellular staining for IFN-γ. Numbers indicate the
percentage of IFN-γ+ CD56bright NK cells. (b) Cumulative data of the IFN-γ expression in
the presence of individual sera. The value of the percentage of IFN-γ+ cells obtained in
the presence of the pooled sera from controls was set as 100% (indicated as dotted line).
Horizontal lines indicate the median and interquartile range. (c) Spearman correlation
between the expression of IFN-γ of CD56bright NK cells of a patient on day 1 and day 8 in
the presence of IL-12 (to correct for the insufﬁcient release of IL-12 from PBMC; as
shown in Fig. 2b) and the expression of IFN-γ of cells from healthy donors in the
presence of the corresponding serum of the patient (as shown in Fig. 4b). iso, isotype
control.
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mentioned above, monocytes are impaired in IL-12 synthesis after se-
vere injury andmight further aggravate the suppression of NK cells [42].
The association between the expression of the IL-12Rβ2 chain and
the IFN-γ production implies that the IL-12Rβ2 chain represents a
check-point in the activity of CD56bright NK cells in systemic inﬂamma-
tion. The promoter of the IL-12RB2 gene contains several binding sites
for diverse activating or repressing transcription factors including
T-bet, STAT4, suppressor of cytokine signalling (SOCS) 3, and NFATc2
[49–52]. The binding afﬁnity of some of these transcriptions factors de-
pends on genetic variants and inﬂuences the transcriptional activity of
the IL-12RB2 gene [53]. Moreover, epigenetic modiﬁcations of the IL-
12RB2 locus have been reported [54]. Any of these regulatory mecha-
nisms should be considered in future studies on the mechanisms that
cause the modulation of CD56bright NK cells in systemic inﬂammation.
In addition, we recognized a decisive role of the microenvironment
in the modulation of CD56bright NK cells after severe injury. When ex-
posed to the patients' sera, CD56bright NK cells from healthy donors
displayed a similar phenotype as CD56bright NK cells from patients
with regard to inhibition of IL-12Rβ2 chain expression, STAT4 phos-
phorylation, and IFN-γ production. In contrast, the patients' sera did
not affect the activity for degranulation of NK cells arguing against a
global inhibition of NK cell function. Importantly, the patients' sera did
not disturb but rather increased the capacity of monocytes to produce
IL-12 in response to S. aureus for so far unknown reasons. Considering
its relevance in the activation of NK cells we, thus, exclude that an insuf-
ﬁcient production of IL-12 by monocytes contributed to the inhibitory
effect of the sera on CD56bright NK cells.
With regard to the enhanced incidence of nosocomial infections in
patients around day 8 after severe injury we propose that the delayed
appearance of the exhaustion-like behaviour of NK cells together with
the sustained inhibitory activity of the serum worsens the resistance
to invading pathogens [48]. In consequence, the restoration of the IL-
12Rβ2 expression on CD56bright NK cells during systemic inﬂammation
might represent a therapeutic target to improve immune defence
mechanisms.
The suppressive effect of the patients' sera on the IL-12Rβ2 expres-
sion of CD56bright NK cells was largely mediated by ALK5/TGF-βRI. In
terms of IFN-γ synthesis, the inhibition of the TGF-βRI did not
completely restore the function of CD56bright NK cells indicating that ad-
ditional inhibitory signalling pathway(s) might be triggered by so far
unknown factors in the patients' sera. In line with previous reports we
did not detect signiﬁcantly elevated levels of the functionally active
form of TGF-β in the serum of the patients [55]. In search of an alterna-
tive agonist of the TGF-βRI we found strongly increased levels of circu-
lating GDF-15 within 24 h after severe injury that persisted for at least
8 d and thus resembled the kinetics of IL-6 though at much higher con-
centration. GDF-15 is considered to limit inﬂammation while elevated
levels of GDF-15 are associated with morbidity such as atherosclerosis,
cardiovascular diseases, cancer, and obesity [37,38,56–60]. Though,
mechanistic studies on GDF-15 in human diseases are rare and have
not considered NK cells so far. Here, we provide ﬁrst evidence for an in-
verse correlation of GDF-15 with the expression of IL-12Rβ2 and IFN-γ
of CD56bright NK cells suggesting that GDF-15 is amajor player in the ex-
trinsic suppression of NK cells in systemic inﬂammation. In this context
we additionally examined the effect of GDF-15-free sera on puriﬁed NK
cells thatwere stimulatedwith IL-12 and IL-18. However the expression
of IL-12Rβ2 on NK cells did not increase in the absence of GDF-15
(Suppl. Fig. 14a) suggesting that the stimulation with cytokines did
not appropriately mimic the activation of NK cells after exposure of
PBMC to S. aureus. When cultured in the absence of human serum, the
Fig. 5. The suppressive effect of the patients' sera on CD56bright NK cell-derived IFN-γ synthesis correlates with a diminished IL-12Rβ2 expression. PBMC from healthy donors were
stimulated with inactivated S. aureus in the presence of 10% pooled sera from healthy control subjects or with serum from individual patients obtained on day 1 and day 8 after injury
(group 1; n = 10). (a) Representative dot plots of IL-12Rβ2 staining. Numbers indicate the percentage of IL-12Rβ2+ CD56bright NK cells. (b) Cumulative data of the IL-12Rβ2
expression in the presence of individual sera. The value of the percentage of IL-12Rβ2+ CD56bright NK cells obtained in the presence of the pooled sera from healthy control subjects
was set as 100% (indicated as dotted line). (c) Spearman correlation between the expression of IL-12Rβ2 (as shown in Fig. 5b) and the production of IFN-γ (as shown in Fig. 4b).
(d) Cumulative data of the activation of STAT4 (pSTAT4) in the presence of individual sera. The value of the ΔMFI in CD56bright NK cells obtained in the presence of the pooled sera
from control subjects was set as 100% (indicated as dotted line). Horizontal lines indicate the median and interquartile range of individual values. Statistical analyses were performed
using the Wilcoxon signed rank test. (e) Isolated monocytes from healthy donors were cultured in the pooled serum from control subjects or from patients 8 d after injury (group 1).
The cells were stimulated with inactivated S. aureus alone or together with recombinant IFN-γ and the release of IL-12 was quantiﬁed. Bars show mean + SD of triplicate cultures and
are representative for 3 separate experiments. Statistically signiﬁcant differences between control sera and the patients' sera were tested using unpaired Student's t-test. ***, p b
0.001*, p b 0.05; ##, p b 0.01 versus serum pool of control subjects.
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addition of recombinant human GDF-15 impaired the expression of IL-
12Rβ2 on NK cells from some but not all healthy donors after stimula-
tion with IL-12 and IL-18 (Suppl. Fig. 14b). One explanation could be
that GDF-15 requires additional factors in human serum to efﬁciently
mediate NK cell suppression.
GDF-15 triggers diverse signalling pathways including the canonical
and non-canonical TGF-βRI pathway in leukocytes and tumour cells and
themore recently discovered GDNF-family receptorα-like (GFRAL)-de-
pendent pathway in neurons indicating the large functional plasticity of
GDF-15 [56,61–65].We showhere that GDF-15 in human serum aswell
as human recombinant GDF-15 activated Smad1/5 but not Smad2/3 in
PBMC in a TGF-βRI-dependent manner. These ﬁndings imply that the
Smad2/3 pathway did not play a role in the TGF-βRI-mediated suppres-
sion of NK cells by the patients' serum.
Unexpectedly, the patients' serum triggered Smad1/5 to a similar
degree as did the serum from healthy control subjects although both
strongly differed in their content of GDF-15. But both responses were
dependent on GDF-15 as its depletion each abolished Smad1/5 signal-
ling. Therefore, we cannot ﬁnally exclude so far unrecognized limita-
tions of the reporter assay regarding the sensitivity or the linearity of
detection that might explain the discrepancy between GDF-15 content
and the generated signal. An alternative explanation is that components
downstream of Smad1/5 (e.g. the balance of co-Smads and inhibitory
Smads) or a non-canonical TGF-βRI pathway were responsible for the
diverse activities of both sera [66,67]. Nevertheless, this open question
does not weaken our conclusion that GDF-15 was the major driver of
serum-induced activation of TGF-βRI signalling. We observed an in-
crease in phosphorylated Smad1/8 in CD56bright NK cells after exposure
to the patients' sera. The promoter of the human IL12RB2 gene contains
several putative binding sites for Smad1/8 (Suppl. Fig. 15). Therefore,
activated Smad1/8 might directly regulate the expression of IL-12Rβ2.
However, we cannot exclude indirect effects on the expression of IL-
12Rβ2 on NK cells through the activation of Smad1/8 in accessory
cells. Thus, the precise link between TGF-βRI-induced activation of
Smad1/8 and IL-12Rβ2 expression on NK cells upon exposure to the pa-
tients' serum remains to be addressed in further studies.
The concentration of GDF-15 in the serum was extraordinarily high
after severe injury and reached values that are otherwise found in pa-
tientswithmetastatic colon cancer orwith sepsis [68,69]. In this context
it is intriguing to speculate that GDF-15 also contributes to the above
mentioned suppression of NK cells in patients suffering from systemic
inﬂammation due to sepsis [23]. Thus, the considerable amount of circu-
lating GDF-15 during systemic inﬂammation might explain the gener-
ally increased risk for nosocomial infections despite the large
Fig. 6. Signalling through TGF-βRImediates the suppressive effect of the patients' sera on CD56bright NK cells. (a) Cultures of PBMC from healthy donorswere set up in 2% pooled sera from
patients obtained at different time points after injury or fromhealthy control subjects (group 1). PBMCwere stimulatedwith inactivated S. aureus in the presence of SB431542 (inhibitor of
the TFG-βRI) or of its solvent (−) and the expression of the IL-12Rβ2 and of IFN-γ on/in CD56bright NK cells was determined. Data showmean+ SEM of n=5 independent experiments.
Statistically signiﬁcant differences were tested using paired Student's t-test. (b) PBMC from healthy donors were set up in sera from individual patients 6 d after injury (group 1; n=10)
and were stimulated with S. aureus in the presence of SB431542 or its solvent. Tukey box plots show the cumulative data on the expression of IL-12Rβ2 on CD56bright NK cells. Statistical
differences were tested using Wilcoxon signed rank test. (c) Concentration of GDF-15 in the sera of individual patients (n = 10) and healthy control subjects (group 1). Horizontal lines
indicate themedian and interquartile range of individual values. (d) Spearman correlation between the concentration of GDF-15 in the sera of individual patients (group 2; day 5 serum;
n=19) and the expression of IL-12Rβ2 (normalized to pooled serum from healthy control subjects thatwas set as 100%) on CD56bright NK cells from healthy donors after exposure to the
sera as described above. $, p b 0.05; $$, p b 0.01; $$$, p b 0.001. *, p b 0.05; **, p b 0.01; ***, p b 0.001 versus control serum. #, p b 0.05; ###, p b 0.001.
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heterogeneity of underlying diseases. Whether GDF-15 is the cause or
the consequence of morbidity in humans is still unclear. In case of the
present study the level of circulating GDF-15 did not correlate with
the extent of tissue injury. The question ‘where’ and ‘why’ GDF-15
was released at these substantial levels after severe tissue damage re-
mains open.
A previous study on a Swedish male cohort demonstrated a large
interindividual variation of the GDF-15 concentration in the blood
and identiﬁed GDF-15 as a predictor for all-cause mortality over
14 years [70]. We observed that patients who later suffered from
septic complications displayed higher GDF-15 levels in the blood as
soon as 1 d after severe injury than patients who remained free of
a septic episode. Due to the lack of serum samples obtained before
severe injury it remains unclear whether patients displaying high
GDF-15 levels represent individuals with high basal levels of this me-
diator. We propose that GDF-15 that circulates during systemic in-
ﬂammation may interfere with the protective immune response to
bacterial infections through the extrinsic suppression of CD56bright
NK cells. Importantly, the quantiﬁcation of GDF-15 in the blood
early after severe injury might help to identify patients with en-
hanced risk for septic complications who might be stratiﬁed for spe-
ciﬁc therapies.
In summary, during systemic inﬂammation TGF-βRI-mediated sig-
nals induce a long-lasting suppression of the IL-12/IFN-γ axis in CD56-
bright NK cells that might interfere with the protective role of NK cells
in the immune defence against invading pathogens. We identiﬁed
GDF-15 not only as an agonist of the TGF-βRI and thereby as a therapeu-
tic target to restore NK cell function in systemic inﬂammation butmore-
over as a potential early marker for patients who are prone to
nosocomial infections during the course of disease.
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Fig. 7.GDF-15 in the serum signals through the canonical TGF-βRI pathway in leukocytes.
PBMC from healthy donors were transfected with CAGA or BRE reporter constructs
indicating activation of Smad2/3 and Smad1/5, respectively. (a) PBMC were exposed to
pooled sera from healthy control subjects or to pooled sera from patients obtained 5 d
after injury each in the absence or presence of SB431542 (inhibitor of the TFG-βRI).
Recombinant TGF-β and BMP-2 served as positive controls for the activation of Smad2/3
and Smad1/5, respectively. (b) Sera were depleted of GDF-15 (αGDF-15) or were
treated with an isotype control antibody (iso) before transfer to the transfected PBMC.
Recombinant GDF-15 was added to PBMC in the absence or presence of SB431542 (SB).
The luciferase activity representing binding of Smad to the reporter constructs was
determined. The luciferase activity in PBMC in the absence of sera or recombinant
proteins was set as 1 and was used to normalize all values. Bar graphs show the mean
+ SEM of n = 5 independent experiments. Signiﬁcant differences were analysed using
the paired Student's t-test. **, p b 0.01; ***, p b 0.001. c, control sera; a.u., arbitrary units.
Fig. 8. Increased levels ofGDF-15 early after injury circulate in patientswho later develop a
septic complication. The concentration of GDF-15 was determined in sera obtained from
patients (group 3; n = 20) 1 d and 5 d after severe injury. The graph depicts individual
values from patients who remained free (n = 10; non-septic) or developed sepsis
beyond day 6 after injury (n = 10; septic). Horizontal lines indicate the median and
interquartile range. Statistical analysis was performed using the Mann Whitney U test.
**, p b 0.01.
Table 2
Circulating GDF-15 levels on day 1 after injury correlate with morbidity.
Age ISS SOFAmax
Spearman r −0.117 0.130 0.658
p value ns ns p b 0.0001
ns, not signiﬁcant.
The correlation of the concentration of GDF-15 in the serum of the patients of all groups
(n=49) 1 d after injurywith the age, the injury severity score (ISS), and themaximal Se-
quential Organ Failure Assessment (SOFAmax) score during the ﬁrst 5 d was tested using
Spearman correlation analysis.
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